Efferon

What Efferon does

Efferon is a privately held biotech company that develops and commercializes patented single-use hemoadsorption cartridges for extracorporeal blood purification in sepsis and septic shock. The company's core products are Efferon LPS (adult) and Efferon NEO (pediatric) — both built on a hypercrosslinked polystyrene (HPS) matrix with a covalently immobilized LPS-selective synthetic ligand that simultaneously removes bacterial endotoxins and excess inflammatory cytokines in a single hemoperfusion pass. Efferon NEO received CE MDR approval in April 2026 as Europe's first hemoadsorption device indicated for neonatal and pediatric sepsis, following the April 2024 CE MDR approval of Efferon LPS. The devices integrate with RRT, ECMO, and cardiopulmonary bypass circuits and are validated by the LASSO multicenter RCT (n=58, published in Shock 2023) and the LASSO NEO multicenter controlled study (n=78, presented at ESICM LIVES 2025), with results showing 28-day mortality of 9% (NEO) vs 35% (control) in pediatric sepsis (p=0.008) and 10% vs 66% hospital mortality in gram-negative sepsis (OR=0.06, p=0.003).

The company operates a partner-driven commercial model, distributing cartridges through 20+ exclusive regional partners across 40+ countries on 4 continents, with Efferon International GmbH (Germany) serving as the central international sales entity. Revenue is generated from one-time cartridge sales (one cartridge per 1–2 hemoperfusion sessions per sepsis patient) plus a white-label/royalty-equivalent stream in Germany (HEMATOPURE DUO via Diamed medTEC). Reimbursement is established in Russia (OMS tariffs) and progressing across EU countries. End customers are primarily adult and pediatric intensive care units, renal replacement therapy centers, and specialty ICUs in tertiary hospitals; named reference sites include Bambino Gesù Children's Hospital (Rome), N.I. Pirogov City Clinical Hospital (Moscow), Sklifosovsky Research Institute, and Krasnoyarsk State Medical University. As of April 2026, more than 25,000 Efferon hemoadsorption treatments have been performed globally.

The company is led by co-founders Dima Romashin (CEO) and Ivan Bessonov (CTO), both originating from Moscow State University Chemistry Faculty research. Legal structure consists of Estonian parent Efferon OÜ and wholly-owned Austrian operating subsidiary Efferon International GmbH (Villach). The company is venture-backed (Fix Ventures, 2021) with 51–100 employees. Expansion is concentrated in EU, MENA, and Latin America following the CE MDR approvals, with new product development targeted at oncology, autoimmune, and chronic inflammatory indications.

Name

Efferon

Legal name

Efferon OÜ

Website

https://efferon.com

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

11–50 employees

Short description

Efferon is a privately held biotech company developing CE-MDR-approved single-use hemoadsorption cartridges (Efferon LPS for adults, Efferon NEO for pediatrics) that simultaneously remove bacterial endotoxins and cytokines from blood in sepsis patients. The company sells through 20+ exclusive distributors across 40+ countries, targeting adult and pediatric ICUs and renal replacement therapy centers in tertiary hospitals.

Ownership category

akta.pro rank

Product category

Extracorporeal Blood Purification Medical Devices

NAICS

Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Renal Replacement Therapy Consumables (Bloodlines, Filters, Cartridges) (HLAHAKAH)

akta.pro secondary industries

Mechanical Circulatory Support (VAD, IABP, ECMO) (HLAHAFAG), Cell & Tissue Banking (biobanking, cord blood/tissue) (HLAAAGAE)

Keywords

• Hemoadsorption devices
• Extracorporeal blood purification
• Sepsis treatment cartridges
• Endotoxin removal systems
• Polysorbent medical devices

Headquarters

HQ city

Villach

HQ country

Austria

HQ region

Europe

Offices4 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure

Revenue model

1. Single-use Hemoadsorption Cartridge Sales: Primary revenue driver: sale of single-use Efferon LPS (adult) and Efferon NEO (pediatric) cartridges to hospitals and ICUs through a network of more than 20 international distribution partners in 40+ countries. Revenue is one-time per cartridge consumed, with the cartridge used in 1–2 hemoperfusion sessions per sepsis patient.
2. Distributor White-Label/Brand Licensing: In Germany, Efferon LPS is sold under the partner brand HEMATOPURE DUO by DIAMED medTEC GmbH, indicating a private-label/OEM arrangement that generates wholesale/royalty-equivalent revenue streams.

Go-to-market motion4 records

Distribution channels25 records

Marketing channels10 records

Core offering

Efferon develops, manufactures, and sells single-use hemoadsorption cartridges (Efferon LPS for adult patients and Efferon NEO for pediatric patients) for extracorporeal blood purification in the treatment of sepsis, septic shock, and multiple organ failure. The devices use a proprietary hypercrosslinked polystyrene matrix with a covalently immobilized LPS-selective synthetic ligand to simultaneously remove bacterial endotoxins and excessive inflammatory cytokines from whole blood during hemoperfusion.

Differentiator

Problem solved

Functional benefit

Brands

• Efferon LPS: Single-use therapeutic device for extracorporeal blood adsorption containing polymeric beads surface-modified with an LPS-selective ligand; the first multimodal hemoadsorption cartridge combining endotoxin and cytokine adsorption, used for sepsis, septic shock and multiple organ failure in adult patients.
• Efferon NEO

Products and services

• Efferon LPS Single-use hemoadsorption cartridge for adult patients (Class 2b medical device). Contains polymeric beads surface-modified with an LPS-selective ligand, used in hemoperfusion to simultaneously remove bacterial endotoxins (LPS) and excessive cytokines from whole blood. Indicated for sepsis, septic shock, gram-negative sepsis, intra-abdominal sepsis, multiple organ failure, and cytokine release syndrome in adult ICU patients. Integrated with RRT, ECMO, and CPB circuits.
• Efferon NEO Single-use hemoadsorption cartridge specifically designed for pediatric and neonatal patients (1 month to 18 years). Europe's first CE MDR-approved multimodal extracorporeal blood purification device for neonatal and pediatric sepsis. Compact polycarbonate column (60 mL inner volume, 30 mL blood filling volume, 130 g) with engineered blood flow rate of 3-7 mL/kg/min. Contains polymeric beads with LPS-selective ligand.

Quantifiable outcome

• 28-day mortality 9% (Efferon NEO) vs 35% (control) in pediatric sepsis (p=0.008, OR=0.2)
• +11 more outcomes

Named customers8 records

Segments5 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration6 records

Feature7 records

Partnerships

26 partnerships are on record, tiered regional (austria), regional (australia/nz — efferon's most geographically distant partner), regional (bulgaria), regional (czech republic + slovakia), flagship (german market — sells efferon lps under hematopure duo white-label brand), regional (greece), regional (hungary), regional (india), regional (iran), regional (israel), flagship (italy — 500+ hospitals; national leader in medical device distribution), flagship (covers 9+ mena markets including ksa), flagship (latin america — covers panama, costa rica, paraguay; long-standing regional partner), flagship (poland — secured 42nd country / 16th eu country approval), flagship (romania — 19+ million people reached; co-hosted srati symposium), regional (western balkans), flagship (three adriatic/mediterranean markets), regional (turkey), regional (vietnam), flagship (five-market international distributor), regional (armenia), flagship (russia — primary distribution partner in home market), strategic (key opinion leader for pediatric ce mdr approval), flagship (international sales coordination entity), flagship (legal parent entity) and strategic (issuance of eu qms certificate for efferon neo).

• Min Medical GmbH (Austria)regional (austria)Channel Partner/ Reseller/ DistributorAustrian medical device distribution company (also known as MIN Medical Innovation) distributing Efferon LPS in Austria. Distribution agreement signed summer 2024.
• Medigroup Australia Pty Ltd (Medigroup EBI)regional (australia/nz — efferon's most geographically distant partner)Channel Partner/ Reseller/ DistributorAustralian medical device distribution company founded in 2004 with a strong track record in securing regulatory approval and reimbursement for niche medical technologies. Handles TGA approval in Australia; became Efferon's 14th international partner in June 2025.
• SaniMed EOD (Bulgaria)regional (bulgaria)Channel Partner/ Reseller/ DistributorBulgarian medical device distribution partner; distribution agreement signed summer 2024. Distributes Efferon LPS in Bulgaria.
• Meditrade Ltd. (Czech Republic, Slovakia)regional (czech republic + slovakia)Channel Partner/ Reseller/ DistributorCentral European medical device distribution partner covering both Czech Republic and Slovakia. Listed on the company contact page as Efferon's exclusive distributor for the territory.
• DIAMED medTEC GmbH (Germany)flagship (german market — sells efferon lps under hematopure duo white-label brand)OEM/ Whitelabel/ Licensing PartnerGerman medical device company that distributes Efferon LPS in Germany under the white-label brand HEMATOPURE DUO. Incorporated Efferon LPS into German Society of Nephrology (DGfN) clinical guidelines for therapeutic apheresis. Co-presented antibiotic removal data at NEPHROLOGIE 2025.
• Verma Drungs SA (Verma Drugs) — Greeceregional (greece)Channel Partner/ Reseller/ DistributorGreek pharmaceutical distribution company; partner for Efferon in Greece. Organized satellite lectures at the 10th Hellenic Haemapheresis Association Conference and the 20th Panhellenic Intensive Care Congress in Athens, November 2025, with Prof. Griveas Ioannis and Prof. George Dimopoulos.
• Medial Kft (Medial Ltd) — Hungaryregional (hungary)Channel Partner/ Reseller/ DistributorHungarian medical device distribution partner; distribution agreement signed summer 2024. Distributes Efferon LPS in Hungary.
• Helmier Private Limited (India)regional (india)Channel Partner/ Reseller/ DistributorIndian medical device distribution partner; listed on the company contact page as the exclusive distributor for India.
• Chista Darman Qeshm Co. (Iran)regional (iran)Channel Partner/ Reseller/ DistributorIranian medical device distribution partner; listed on the company contact page as the exclusive distributor for Iran.
• Systemedic Ltd. (Israel)regional (israel)Channel Partner/ Reseller/ DistributorIsraeli medical device distribution partner; listed on the company contact page as the exclusive distributor for Israel.
• Gada Italia (Palex Group) — Italyflagship (italy — 500+ hospitals; national leader in medical device distribution)Channel Partner/ Reseller/ DistributorItalian medical device distribution company of the Palex Group with 40+ years of experience; works with 500+ hospitals and clinics across Italy. Partnership launched July 2025.
• EXPERTS MED TRADING CO. L.L.C. (ExpertsMed) — MENAflagship (covers 9+ mena markets including ksa)Channel Partner/ Reseller/ DistributorMedical device distribution company with strong expertise in emerging markets and a presence across more than 100 markets. Covers Egypt, South Africa, UAE, Kuwait, Morocco, Libya, Oman, Qatar, Bahrain, and the Kingdom of Saudi Arabia. Secured Saudi FDA (SFDA) marketing authorization for Efferon LPS in October 2025.
• US Pharmacy Systems INC (US Pharmacy Group) — Latin Americaflagship (latin america — covers panama, costa rica, paraguay; long-standing regional partner)Channel Partner/ Reseller/ DistributorLatin American medical device distribution partner with strong professional network across the region. Distributes Efferon LPS in Panama, Costa Rica, and Paraguay. Secured Costa Rica approval in February 2026 (Efferon's 41st country).
• West Medical — Polandflagship (poland — secured 42nd country / 16th eu country approval)Channel Partner/ Reseller/ DistributorPolish medical device distribution partner with deep knowledge of the Polish healthcare system and long-standing experience. Secured official authorization for Efferon in Poland in March 2026.
• Smart Medical Solutions SRL — Romania / Moldovaflagship (romania — 19+ million people reached; co-hosted srati symposium)Channel Partner/ Reseller/ DistributorMajor and well-established player in the Romanian medical device market. Distributes Efferon LPS in Romania and Moldova. Co-hosted the 51st SRATI Congress symposium in Sinaia with Prof. Jan T. Kielstein, Prof. Dana Tomescu, and Prof. Dan Corneci.
• Medicon doo Dec — Serbia, Bosnia and Herzegovina, Montenegroregional (western balkans)Channel Partner/ Reseller/ DistributorWestern Balkans medical device distribution partner covering Serbia, Bosnia and Herzegovina, and Montenegro. Listed on the company contact page.
• Bertossi Co. Ltd. — Slovenia, Croatia, Cyprusflagship (three adriatic/mediterranean markets)Channel Partner/ Reseller/ DistributorCypriot medical device distribution company founded in 1991, specializing in highest-quality products and services. Partnership launched April 2025 and introduced at the 3rd International Conference on Extracorporeal Organ Support in Dubrovnik. Distributes Efferon LPS in Slovenia, Croatia, and Cyprus.
• Dateks Teknik Sistemler AS — Turkeyregional (turkey)Channel Partner/ Reseller/ DistributorTurkish medical device distribution partner; distribution agreement signed summer 2024. Distributes Efferon LPS in Turkey.
• Minchoo JSC. — Vietnamregional (vietnam)Channel Partner/ Reseller/ DistributorVietnamese medical device distribution partner; listed on the company contact page as the exclusive distributor for Vietnam.
• NorrDia AB — UK, Ireland, Spain, Colombia, Thailandflagship (five-market international distributor)Channel Partner/ Reseller/ DistributorInternational medical device distribution partner covering five markets across Europe, Latin America, and Asia. Secured MHRA (UK) and Thailand approvals; supports Colombian presence. Distributes Efferon LPS in UK, Ireland, Spain, Colombia, and Thailand.
• Marg Pharma — Armeniaregional (armenia)Channel Partner/ Reseller/ DistributorArmenian medical equipment and disposables specialist in operation since 1997. Introduced Efferon multimodal hemoadsorption therapy to Armenia at the Congress of Anaesthesiologists and Intensive Care Specialists of Armenia in November 2025.
• Nanolek (Нанолек) — Russiaflagship (russia — primary distribution partner in home market)Channel Partner/ Reseller/ DistributorRussian pharmaceutical and medical device company that represents Efferon in the Russian market. Co-markets Efferon devices (Efferon CT/LPS) with device samples at the Nanolek stand at the Federation of Anesthesiologists and Resuscitators (FAR) congress in Moscow. Supports the OМС (mandatory health insurance) reimbursement pathway.
• Bambino Gesù Children's Hospital, IRCCS, Rome, Italystrategic (key opinion leader for pediatric ce mdr approval)OthersPediatric Intensive Care Unit led by Dr. Gabriella Bottari, who provided a key KOL quote supporting Efferon NEO's CE MDR approval. Bambino Gesù is a leading European pediatric research hospital participating in the LASSO NEO study.
• Efferon International GmbHflagship (international sales coordination entity)Strategic or Co-development PartnerEfferon's central international sales entity, listed as the "International" contact. Coordinates international sales and distribution-partner relationships; listed as a German investor in Riga by Riga Investment and Tourism Agency (2026 report). The website lists it as the central contact point alongside the in-country distributor network.
• Efferon OÜflagship (legal parent entity)Strategic or Co-development PartnerEstonian legal entity (parent company) that holds the Efferon® brand and serves as the in-country distributor for Estonia. Listed in website copyright footer (© 2023–2026 Efferon OÜ).
• 3EC International (Notified Body 2265)strategic (issuance of eu qms certificate for efferon neo)OthersEU Notified Body 2265 that issued Efferon NEO's EU QMS Certificate No. 2024-MDR/QS-024/A on April 7, 2026 under EU Regulation 2017/745 (MDR), the first such pediatric hemoadsorption approval in Europe.

Scale indicators16 records

Recent moves13 records

Expansion highlights6 records

Emerging players

• ExThera Medical: ExThera Medical develops the Seraph 100 Microbind Affinity Blood Filter, which removes pathogens and inflammatory mediators from blood. Like Efferon, it targets bloodstream-infection and sepsis indications with a single-use cartridge, though via a different binding chemistry.
• Spectral Medical: Spectral Medical is developing Toraymyxin (PMX) for endotoxin removal in septic AKI for the U.S. market via the TIGRIS trial. While U.S.-focused, it is a relevant emerging peer in the endotoxin-selective hemoperfusion category that Efferon LPS competes with in clinical positioning.
• oXiris (Baxter / Eurofarma licensed): The oXiris filter is an AN69 membrane hemofilter with endotoxin-adsorbing surface widely used in CRRT circuits for septic AKI. It competes for the same clinical niche (sepsis + RRT) as Efferon LPS and is often used in head-to-head ICU protocol decisions.

Broad incumbents

• Fresenius Medical Care: Fresenius Medical Care is the world's largest dialysis and RRT manufacturer (multiFiltrate, FX-series hemofilters). Efferon LPS is designed to integrate with Fresenius RRT circuits, making Fresenius both a potential ecosystem partner and a broad incumbent whose installed base can either accelerate or constrain Efferon's growth.
• Baxter International (Prismaflex): Baxter's Prismaflex and HF440 sets are CRRT platforms that explicitly integrate with Efferon LPS in POSTfilter mode. As the dominant Western CRRT incumbent, Baxter is both an integration partner (documented compatibility) and a strategic competitor for ICU spend.
• B. Braun (Diapact / Omni): B. Braun manufactures CRRT and hemoperfusion machines used in ICUs and dialysis centers, and is part of the broader RRT/apheresis ecosystem that hosts Efferon cartridges. As a large incumbent with broad ICU device portfolios, it represents both a distribution channel and competitive threat.

Direct peers

• CytoSorbents Corporation: CytoSorbents makes CytoSorb, a whole-blood cytokine adsorption cartridge used in ICU sepsis, cardiac surgery, and other inflammatory conditions. It is the closest direct competitor to Efferon LPS in the extracorporeal cytokine removal category, sold in 100+ countries.
• Toray Medical / Toray Industries (Toraymyxin): Toraymyxin (PMX-20R) is the polymyxin-B immobilized fiber cartridge that has long dominated endotoxin-selective hemoperfusion in Japan and is also approved in Europe. Efferon LPS is positioned as a next-generation alternative targeting the same LPS-selective indication with broader cytokine coverage.
• Jafron Biomedical: Jafron is the leading Chinese hemoadsorption cartridge maker (HA series - HA330, HA380), sold globally for sepsis and inflammatory conditions. They are a directly comparable cartridge-based hemoadsorption peer with overlapping target customers (ICU physicians, distributors).
• Asahi Kasei Medical (Cellsorba): Asahi Kasei markets Cellsorba, a cytokine-adsorbing column used in Japan and parts of Asia for sepsis and autoimmune conditions. It directly overlaps with Efferon LPS in the cytokine-adsorption indication and shares the ICU intensivist customer base.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/@Efferon-international
• LinkedInlinkedin.com/company/efferon

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Subsidiaries1 record

Funding overview

Funding rounds3 records

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Efferon